However, clinical experience with IL-6 pathway blockade in MS remains limited and heterogeneous—ranging from isolated benefit in fulminant pediatric MS to sporadic reports of MS onset during IL-6R inhibition for rheumatoid arthritis (28, 29)—and its therapeutic value in MS requires further evaluation (30). This evidence concerns the gene IL6R and myeloid sarcoma.